Press Releases

Friday, January 3, 2014

PHILADELPHIA — Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with this disease,

Friday, January 3, 2014

BUFFALO, NY — On January 20 after morning practice, five Buffalo Sabres will shave their heads in front of cancer patients and fans to show their support of people in our community who are fighting cancer.  

Tuesday, December 31, 2013

BUFFALO, NY — A team led by Fengzhi Li, PhD, of Roswell Park Cancer Institute has reported significant new findings regarding the chemical structure of the novel anticancer agent FL118.

Friday, December 27, 2013

Twenty-four physicians from Roswell Park Cancer Institute (RPCI) have been named to Castle Connolly Medical Ltd.’s 2014 America’s Top Doctors list. The list is compiled annually on the basis of recommendations from physicians. A regional Top Doctors directory appears in the January issue of Buffalo Spree magazine.

Tuesday, December 17, 2013

BUFFALO, NY — Timikia C. Craig, a certified nurse’s aide at Roswell Park Cancer Institute (RPCI), is the recipient of the $1,000 Eva M. Noles Scholarship for 2013. The 6th annual Eva M.

Monday, December 16, 2013

BUFFALO, NY — Proteins called fibroblast growth factor receptors (FGFRs) have been implicated in the development of pancreatic cancer, which remains difficult to treat.

Friday, December 13, 2013

Roswell Park Cancer Institute announces two key executive appointments: Armen Gallucci, FACHE, has joined RPCI as Vice President of Business Development and Outreach, and Kerry L. Kerlin has been named Chief Information Officer.

Thursday, December 12, 2013

Electronic cigarettes, when used indoors, may involuntarily expose non-users to nicotine, according to a study led by Maciej Goniewicz, PhD, PharmD, of Roswell Park Cancer Institute and published by the journal Nicotine and Tobacco Research.

Wednesday, December 11, 2013

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. One of the studies will assess how patients’ immune systems respond to targeted radiation treatments for metastatic kidney cancer. Another will evaluate how patients’ immune systems respond to targeted radiation treatments for metastatic prostate cancer, in combination with immunotherapy, and a third will focus on a new type of immunotherapy for bladder cancer.

Saturday, December 7, 2013

Jasco Pharmaceuticals, LLC announced that preclinical data on its PIM inhibitor program would be presented at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition to be held on December 7-10 in New Orleans, LA. The poster will be presented on Saturday, December 7, 2013 from 5:30 PM - 7:30 PM at Exhibit Hall G, Ernest N. Morial Convention Center, abstract 1931. The results will include data generated by the lab of Dr. Kelvin Lee of the Department of Immunology at Roswell Park Cancer Institute (RPCI) in Buffalo, NY, in collaboration with Jasco and with the Center for Drug Development at RPCI.

Wednesday, November 27, 2013

Roswell Park Cancer Institute (RPCI) is pleased to announce the appointment of two directors to key positions in our clinical and business administrative staffs. Kara Eaton-Weaver has been promoted to Executive Director of RPCI’s Patient/Family Experience Department, and Harl Tolbert is the new Director of Technology Transfer and Commercial Development.

Tuesday, November 26, 2013

BUFFALO, NY — Roswell Park Cancer Institute’s (RPCI’s) annual Tree of Hope lighting ceremony will be held on Friday, Dec. 6 from 4:30 to 6:30 p.m. in Kaminski Park and Gardens on the RPCI campus.